Jeffery T Zobell

Summary

Affiliation: Intermountain Medical Center
Country: USA

Publications

  1. doi request reprint High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT 84113, USA
    J Cyst Fibros 9:280-3. 2010
  2. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Pulmonol 48:525-37. 2013
  3. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah 84113, USA
    Pediatr Pulmonol 48:107-22. 2013
  4. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT, USA
    Pediatr Pulmonol 47:1147-58. 2012
  5. doi request reprint A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT 84113, USA
    Pediatr Pulmonol 46:987-90. 2011
  6. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
    Chris Stockmann
    Division of Pediatric Infectious Disease, University of Utah, Salt Lake City, UT 84108, USA
    Pediatr Pulmonol 48:211-20. 2013
  7. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah 84112, USA
    Pediatr Pulmonol 48:1-7. 2013
  8. doi request reprint Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Ther 33:1844-50. 2011
  9. doi request reprint Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Catherine M T Sherwin
    Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    J Pharmacokinet Pharmacodyn 41:71-9. 2014
  10. doi request reprint Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis
    Chris Stockmann
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
    Pharmacotherapy 33:1288-96. 2013

Collaborators

  • Catherine M T Sherwin
  • Chris Stockmann
  • David C Young
  • Krow Ampofo
  • Michael G Spigarelli
  • C Dustin Waters
  • John F Pohl
  • Blakeslee E Noyes
  • Jared Olson
  • Lisa Lubsch
  • Kody Crowell
  • Mark W MacKay
  • Ellen Lin
  • Aleesha Richman
  • Barbara A Chatfield
  • Christian Larsen
  • E Kent Korgenski
  • Raza Patel

Detail Information

Publications12

  1. doi request reprint High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT 84113, USA
    J Cyst Fibros 9:280-3. 2010
    ..This dosing strategy is higher than the Cystic Fibrosis Foundation (CFF) recommendations and the Food and Drug Administration (FDA) approved package labeling. The purpose is to determine the safety of this dosing regimen...
  2. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Pulmonol 48:525-37. 2013
    ....
  3. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah 84113, USA
    Pediatr Pulmonol 48:107-22. 2013
    ..The usefulness of high dose piperacillin (>600 mg/kg/day) may be limited due to treatment-related adverse effects. Further understanding of these adverse effects in CF patients is needed...
  4. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT, USA
    Pediatr Pulmonol 47:1147-58. 2012
    ..The usefulness of imipenem-cilastatin may be limited due to the rapid development of resistance...
  5. doi request reprint A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT 84113, USA
    Pediatr Pulmonol 46:987-90. 2011
    ..While this is of concern, it is not known if optimization of dosing strategies according to guidelines recommendations will result in clinical benefit...
  6. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
    Chris Stockmann
    Division of Pediatric Infectious Disease, University of Utah, Salt Lake City, UT 84108, USA
    Pediatr Pulmonol 48:211-20. 2013
    ..Further study is needed to determine the tolerability and efficacy of levofloxacin in APE. At this time, the routine use of levofloxacin in the treatment of APE in pediatric and adult patients cannot be recommended...
  7. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah 84112, USA
    Pediatr Pulmonol 48:1-7. 2013
    ..thrice-daily) and its impact on resistance and clinical efficacy. Further study is needed to determine the tolerability and efficacy of extended-interval dosing of CMS in the treatment of APE...
  8. doi request reprint Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Ther 33:1844-50. 2011
    ..This dosing strategy is higher than the Food and Drug Administration (FDA)-approved package labeling. We evaluated the microbiologic efficacy of this dosing regimen...
  9. doi request reprint Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Catherine M T Sherwin
    Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    J Pharmacokinet Pharmacodyn 41:71-9. 2014
    ..In simulations, once daily dosing was the only regimen to achieve the pharmacodynamic target for all subjects with MICs <2 μg/mL. ..
  10. doi request reprint Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis
    Chris Stockmann
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
    Pharmacotherapy 33:1288-96. 2013
    ..However, no studies have characterized the pharmacokinetic profile of vancomycin among pediatric cystic fibrosis patients...
  11. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah Intermountain Cystic Fibrosis Adult Center, Salt Lake City, Utah
    Pediatr Pulmonol 48:1047-61. 2013
    ..aeruginosa resistance with once-daily administration of tobramycin...
  12. pmc Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients
    John F Pohl
    Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Primary Children s Medical Center, University of Utah School of Medicine, Salt Lake City, UT 84113 1103, USA
    Gastroenterol Res Pract 2011:345012. 2011
    ..In summary, C. diff infection is more common in hospitalized pediatric CF patients although PPI use may not be a risk factor for CDAD development in this patient population...